The Experts below are selected from a list of 34245 Experts worldwide ranked by ideXlab platform
Kelly A Frazer - One of the best experts on this subject based on the ideXlab platform.
-
discovery of novel plasma biomarkers for Future Incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics
Journal of Thrombosis and Haemostasis, 2018Co-Authors: Soren B Jensen, Kristian Hindberg, Terry Solomon, Erin N Smith, John D Lapek, D J Gonzalez, Nadezhda Latysheva, Kelly A FrazerAbstract:Essentials Discovery of predictive biomarkers of venous thromboembolism (VTE) may aid risk stratification. A case-control study where plasma was sampled before the occurrence of VTE was established. We generated untargeted plasma proteomic profiles of 200 individuals by use of mass spectrometry. Assessment of the biomarker potential of 501 proteins yielded 46 biomarker candidates. Abstract Background Prophylactic anticoagulant treatment may substantially reduce the incidence of venous thromboembolism (VTE) but entails considerable risk of severe bleeding. Identification of individuals at high risk of VTE through the use of predictive biomarkers is desirable in order to achieve a favorable benefit-to-harm ratio. Objective We aimed to identify predictive protein biomarker candidates of VTE. Methods We performed a case-control study of 200 individuals that participated in the Tromso Study, a population-based cohort, where blood samples were collected before the VTE events occurred. Untargeted tandem mass tag-synchronous precursor selection-mass spectrometry (TMT-SPS-MS3)-based proteomic profiling was used to study the plasma proteomes of each individual. Results Of the 501 proteins detected in a sufficient number of samples to allow multivariate analysis, 46 proteins were associated with VTE case-control status with P-values below the 0.05 significance threshold. The strongest predictive biomarker candidates, assessed by statistical significance, were transthyretin, vitamin K-dependent protein Z and protein/nucleic acid deglycase DJ-1. Conclusions Our untargeted approach of plasma proteome profiling revealed novel predictive biomarker candidates of VTE and confirmed previously reported candidates, thereby providing conceptual support for the validity of the study. A larger nested case-control study will be conducted to validate our findings.
Akiko Tamakoshi - One of the best experts on this subject based on the ideXlab platform.
-
ankle brachial index is a predictor of Future Incident chronic kidney disease in a general japanese population
Journal of Atherosclerosis and Thrombosis, 2019Co-Authors: Hiroshi Sonoda, Koshi Nakamura, Akiko TamakoshiAbstract:Aims: The ankle-brachial index (ABI) can be a prognostic marker for chronic kidney disease (CKD) in Western populations. Since there is little relevant evidence for Asian populations, we investigated the relationship between ABI and the risk of Incident CKD in a general Japanese population. Methods: The cohort included 5,072 participants aged 30–79 without a history of renal disease or cerebro-cardiovascular disease. Incident CKD, defined as an estimated glomerular filtration rate < 60 (mL/min/1.73 m2) and/or proteinuria (≥ 1 + on urine dipstick), was compared among participants grouped according to baseline ABI: 0.90–0.99, 1.00–1.09, 1.10–1.19, 1.20–1.29, and 1.30–1.39. Hazard ratios for Incident CKD were estimated using a Cox proportional hazards model, with the ABI 1.10–1.19 group serving as the reference. Results: The CKD incidence rate (/100 person-years) was 1.80 during the mean follow-up period of 5.1 years. The CKD incidence rate was 3.04 in the ABI category 0.90–0.99, 1.58 in ABI 1.00–1.09, 1.72 in ABI 1.10–1.19, 2.01 in ABI 1.20–1.29, and 3.33 in ABI 1.30–1.39. The hazard ratios for developing CKD were 2.14 (95% confidence interval 1.16–3.92) in ABI 0.90–0.99, 1.08 (0.83–1.41) in ABI 1.00–1.09, 1.03 (0.83–1.29) in ABI 1.20–1.29, and 1.37 (0.77–2.47) in ABI 1.30–1.39, after adjusting for age, sex, systolic blood pressure, diabetes, and other confounding factors. Conclusions: In a general Japanese population, an ABI of 0.90–0.99 was associated with an increased risk of Incident CKD, independent of traditional cardiovascular risk factors.
Wataru Shoin - One of the best experts on this subject based on the ideXlab platform.
-
prognostic value of ankle brachial index for Future Incident heart failure in patients without previous heart failure data from the impressive predictive value of ankle brachial index for clinical long term outcome in patients with cardiovascular disease examined by abi study
Heart and Vessels, 2017Co-Authors: Hitoshi Nishimura, Takashi Miura, Masatoshi Minamisawa, Yasushi Ueki, Naoyuki Abe, Naoto Hashizume, Tomoaki Mochidome, Mikiko Harada, Kunihiko Shimizu, Wataru ShoinAbstract:The ankle brachial index (ABI) is regarded as a predictor of Future cardiovascular events. However, the relationship between ABI and Incident heart failure (HF) in patients without previous HF is poorly understood. This study aimed to assess the prognostic value of ABI for Incident HF in patients without previous HF. The IMPACT–ABI study was a retrospective, single-center, cohort study that enrolled and measured ABI in 3131 patients hospitalized for cardiovascular disease between January 2005 and December 2012. From this cohort, 307 patients were excluded because of previous HF and high (>1.4) ABI. The remaining 2824 patients were stratified into three groups: low ABI (≤0.9), borderline ABI (0.91–0.99), and normal ABI (1.0–1.4). The primary endpoint was hospitalization for HF. Over a mean 4.8-year follow-up, 105 cases of HF occurred. The cumulative incidence of HF was significantly higher in patients with low and borderline ABIs than in those with normal ABI (19.3 vs. 21.0 vs. 10.4 %, log rank P <0.001). In multivariate Cox proportional hazard analysis, low ABI and borderline ABI were independent predictors of Incident HF [hazard ratio (HR) 3.00; 95 % confidence interval (CI) 1.70–5.28; P < 0.001 and HR 2.68; 95 % CI 1.35–5.34; P = 0.005, respectively]. In conclusion, low and borderline ABI were strong predictors for Future Incident HF in patients without previous HF.
Lei Chen - One of the best experts on this subject based on the ideXlab platform.
-
maximizing efficiency and cost effectiveness of type 2 diabetes screening the ausdiab study
Diabetic Medicine, 2011Co-Authors: Lei Chen, Dianna J Magliano, Beverley Balkau, Rory Wolfe, Laurie Brown, Andrew Tonkin, Paul Zimmet, Jonathan E ShawAbstract:Diabet. Med. 28, 414–423 (2011) Abstract Aims To evaluate how to most efficiently screen populations to detect people at high risk of Incident Type 2 diabetes and those with prevalent, but undiagnosed, Type 2 diabetes. Methods Data from 5814 adults in the Australian Diabetes, Obesity and Lifestyle study were used to examine four different types of screening strategies. The strategies incorporated various combinations of cut-points of fasting plasma glucose, the non-invasive Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK1) and a modified version of the tool incorporating fasting plasma glucose (AUSDRISK2). Sensitivity, specificity, positive predictive value, screening costs per case of Incident or prevalent undiagnosed diabetes identified and intervention costs per case of diabetes prevented or reverted were compared. Results Of the four strategies that maximized sensitivity and specificity, use of the non-invasive AUSDRISK1, followed by AUSDRISK2 in those found to be at increased risk on AUSDRISK1, had the highest sensitivity (80.3%; 95% confidence interval 76.6–84.1%), specificity (78.1%; 95% confidence interval 76.9–79.2%) and positive predictive value (22.3%; 95% confidence interval 20.2–24.4%) for identifying people with either prevalent undiagnosed diabetes or Future Incident diabetes. It required the fewest people (24.1%; 95% confidence interval 23.0–25.2%) to enter lifestyle modification programmes, and also had the lowest intervention costs and combined costs of running screening and intervention programmes per case of diabetes prevented or reverted. Conclusions Using a self-assessed diabetes risk score as an initial screening step, followed by a second risk score incorporating fasting plasma glucose, would maximize efficiency of identifying people with undiagnosed Type 2 diabetes and those at high risk of Future diabetes.
Lisa M Shin - One of the best experts on this subject based on the ideXlab platform.
-
amygdalar activity predicts Future Incident diabetes independently of adiposity
Psychoneuroendocrinology, 2019Co-Authors: Michael T Osborne, Amorina Ishai, Basma Hammad, Brian Tung, Ying Wang, Amos Baruch, Zahi A Fayad, Jon T Giles, Lisa M ShinAbstract:Abstract While it is established that psychosocial stress increases the risk of developing diabetes mellitus (DM), two key knowledge gaps remain: 1) the neurobiological mechanisms that are involved in mediating that risk, and 2) the role, if any, that adiposity plays in that mechanism. We tested the hypotheses that: 1) metabolic activity in the amygdala (AmygA), a key center involved in the neurobiological response to stress, associates with subsequent DM risk, and 2) this association is independent of adiposity. AmygA and adipose tissue volumes were measured, and serial blood assessments for DM were obtained in 232 subjects who underwent combined 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) imaging. Higher baseline AmygA predicted subsequent, new-onset DM, independently of adiposity and other DM risk factors. Furthermore, higher adiposity only increased DM risk in the presence of higher AmygA. In a separate cross-sectional cohort, higher AmygA associated with higher insulin resistance. Accordingly, the current study shows, for the first time, that activity in a stress-responsive neural region predicts the onset of DM. Further, we observed that this neurobiological activity acts independently of, but also synergistically with adiposity to increase DM risk. These findings suggest novel therapeutic targets to help manage and possibly prevent DM.
